We read the article by Shaw et al 1 with great interest. The administration of a single daily busulfan dose has several practical advantages over traditional q6h dosing. First, as Shaw et al 1 have pointed out, a more accurate evaluation of AUC is possible even in patients with a prolonged absorption phase. Second, nursing and pharmacy workload is reduced and some patients may find it less bothersome to take 1 dose each day.
These points are perhaps counterbalanced by practical disadvantages such as the need for children to swallow large numbers of tablets within a short period of time. For example, a child of 1 m 2 taking a 150 mg dose would be asked to swallow 75 2 mg busulfan tablets. In our experience, many patients will vomit oral busulfan doses and many will require an NG tube to take each dose successfully. Shaw et al 1 did not mention the maximum time period in which children were expected to take the entire dose or their strategy when a child vomited soon after dose administration.
While Grochow 2 and Dix 3 have shown that the probability of developing veno-occlusive disease (VOD) in adults is higher if the busulfan area under curve (AUC) is more than 1500 mM min after q6h administration, this relationship is not perhaps as strong in children. 4, 5 The relationship between AUC and engraftment may be more important in children, particularly in those who have higher apparent oral busulfan clearance such as children o4 years. 6 It is noteworthy that Shaw et al 1 reported engraftment failure in one out of four children younger than 3 years of age. This child had an AUC of 4005 mM min, despite receiving a dose of 150 mg/m 2 for 4 days. We have previously reported no difference in the incidence of event-free survival, graft failure or conjugated hyperbilirubinemia among 84 children who received cyclophosphamide and either busulfan p600 mg/m 2 or 4600 mg/m 2 . 2,7 Recent information suggests that patients with increased busulfan total body clearance after oral administration due to glutathione S-transferase polymorphism may be at a higher risk of VOD. 8 Such patients would have a low busulfan AUC. Clearly, the optimum pediatric pharmacokinetic targets of busulfan and the dose required to achieve them remain unknown.
Previous descriptions of the relationship between busulfan pharmacokinetic parameters (AUC and Css) and either VOD or engraftment have been made in the context of q6h dosing, either PO or IV. The concept of aggregating the target AUC derived from q6h dosing to a daily target is valid only if the higher C max and higher busulfan concentration presented to the liver on the first pass after oral administration does not lead to increased toxicity. This is apparently the case, since Shaw et al 1 report very low rates of VOD and regimen-related toxicity although differences in C max were not specifically described. Oral busulfan administration, whether q24h or q6h, will always be complicated by patient tolerability and wide interpatient variation in bioavailability. Both issues are obviated by its i.v. administration. It cannot be assumed that the accepted pharmacokinetic targets after oral busulfan administration apply to its i.v. administration. The safety and efficacy of once-daily i.v. busulfan administration requires meticulous study similar to that carried out by Shaw et al 1 with PO administration. Regardless of its route of administration, more information regarding busulfan disposition and appropriate dosing in patients with a broad range of underlying conditions and receiving various conditioning regimens is required before the individual dose adjustment based on assessment of busulfan disposition can be abandoned. Ideally, such studies should also incorporate an examination of the influence of pharmacogenetic factors such as glutathione S-transferase genotype 8 and an estimation of the effect of cyclophosphamide metabolites on transplant outcomes. 
